Core Insights - Dyne Therapeutics is set to present five key presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, showcasing advancements in their neuromuscular disease programs, particularly in Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and Pompe disease [1][2]. Group 1: Presentation Highlights - The company will present new long-term data from the DELIVER trial in DMD, indicating potential preservation of cardiopulmonary function [2][4]. - A robust Phase 3 trial design for z-basivarsen in DM1 will be discussed, which is anticipated to be field-defining [2][3]. - Dyne's pipeline demonstrates strength through the FORCE™ platform, which is validated by clinical data showing functional improvements across various muscle groups [2][4]. Group 2: Oral and Poster Presentations - Oral presentations will include significant findings on z-rostudirsen's impact on dystrophin protein levels and functional improvements in DMD [3]. - The design of a global Phase 3 trial for z-basivarsen in DM1 will be presented, along with preclinical data for DYNE-401 targeting Pompe disease [3][4]. - Poster presentations will feature late-breaking data on z-rostudirsen's long-term clinical outcomes and new analyses from the DELIVER trial [4][5]. Group 3: Conference Details - The conference will take place from March 8-11, 2026, in Orlando, FL, and virtually, with all presentations available on Dyne's website [1][6]. - A symposium titled "Functional improvement: Moving beyond dystrophin in DMD" is scheduled for March 9, 2026 [6].

Core Insights - Dyne Therapeutics is showcasing its advancements in neuromuscular disease treatments at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, with five presentations highlighting its pipeline [2][3] Group 1: DELIVER Trial Results - The DELIVER trial for z-rostudirsen in Duchenne muscular dystrophy (DMD) has shown positive topline results, indicating significant functional improvement across various muscle groups, including cardiopulmonary function [3][5] - New long-term data from the DELIVER trial will be presented, emphasizing the potential preservation of cardiopulmonary function [3][5] Group 2: Pipeline Developments - Dyne is presenting the design of a Phase 3 trial for z-basivarsen in myotonic dystrophy type 1 (DM1), which is expected to be a field-defining study [3][4] - Preclinical data for DYNE-401, aimed at addressing Pompe disease, will also be shared, demonstrating the potential for low and infrequent dosing to achieve functional improvement [4][5] Group 3: Presentation Details - The conference will feature three oral presentations, including one on the efficacy and safety of z-basivarsen in DM1 and another on the functional improvements associated with z-rostudirsen in DMD [4][6] - Poster presentations will include additional analyses from the DELIVER trial and the design of the Phase 3 trial for z-basivarsen [5][6] Group 4: Company Mission and Focus - Dyne Therapeutics is dedicated to delivering functional improvements for individuals with genetically driven neuromuscular diseases, focusing on therapies that target muscle and the central nervous system [8]